Liquidia (NASDAQ:LQDA) Now Covered by Wells Fargo & Company

Equities research analysts at Wells Fargo & Company assumed coverage on shares of Liquidia (NASDAQ:LQDA) in a report issued on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $20.00 price target on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 88.86% from the company’s previous close.

A number of other equities analysts have also issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th. Finally, Scotiabank started coverage on shares of Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.60.

Liquidia Stock Down 0.9 %

Shares of NASDAQ LQDA opened at $10.59 on Friday. The business has a 50-day moving average price of $10.91 and a 200 day moving average price of $11.20. The stock has a market cap of $896.31 million, a PE ratio of -6.50 and a beta of 0.22. Liquidia has a 52-week low of $7.76 and a 52-week high of $16.99.

Insider Activity at Liquidia

In related news, insider Rajeev Saggar sold 2,260 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the transaction, the insider now directly owns 207,383 shares in the company, valued at $2,304,025.13. The trade was a 1.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Michael Kaseta sold 3,892 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $43,240.12. Following the sale, the chief financial officer now directly owns 311,076 shares in the company, valued at approximately $3,456,054.36. The trade was a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,007 shares of company stock worth $245,780 over the last 90 days. Company insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Partners LLC acquired a new stake in Liquidia in the 2nd quarter worth about $27,000. Deuterium Capital Management LLC purchased a new stake in shares of Liquidia during the 2nd quarter worth about $120,000. Clear Harbor Asset Management LLC purchased a new position in Liquidia in the third quarter valued at approximately $100,000. Signaturefd LLC lifted its position in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new stake in Liquidia during the third quarter worth approximately $110,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).